Johnson & Johnson (JNJ) Position Lifted by Mascoma Wealth Management LLC
Mascoma Wealth Management LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 7.2% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 8,196 shares of the company’s stock after buying an additional 554 shares during the quarter. Johnson & Johnson makes up about 0.7% of Mascoma Wealth Management LLC’s investment portfolio, making the stock its 24th largest position. Mascoma Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,066,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Harding Loevner LP bought a new position in Johnson & Johnson in the 2nd quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its holdings in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the period. Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson in the 2nd quarter worth $124,000. Shine Investment Advisory Services Inc. bought a new position in Johnson & Johnson in the 2nd quarter worth $177,000. Finally, Lenox Wealth Management Inc. boosted its holdings in Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after buying an additional 24 shares during the period. 65.53% of the stock is owned by institutional investors.
Shares of Johnson & Johnson (JNJ) opened at $130.27 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The stock has a market cap of $349,970.00, a PE ratio of 334.03, a PEG ratio of 2.33 and a beta of 0.74. Johnson & Johnson has a 1 year low of $115.22 and a 1 year high of $148.32.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.58%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is 861.54%.
Several research firms have commented on JNJ. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a report on Wednesday, October 18th. JPMorgan Chase & Co. downgraded shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price objective for the company in a report on Wednesday, December 20th. BMO Capital Markets increased their price objective on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Finally, BTIG Research reissued a “sell” rating and set a $110.00 price objective on shares of Johnson & Johnson in a report on Wednesday, January 24th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $146.16.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.